ArticleHuman vaccines & immunotherapeutics2026
Passive surveillance of adverse events following immunization for National Immunization Program vaccines in Shenyang, China, 2009-2024.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the Chinese National Adverse Events Following Immunization Surveillance Information System (CNAEFIS), a descriptive epidemiological analysis was conducted on Adverse Events Following Immunization (AEFI) of National Immunization Program (NIP) vaccines in Shenyang from 2009 to 2024, to understand the distribution characteristics and reporting status of AEFI using passive surveillance data in the region. Reaction types were classified according to national unified surveillance standards. Descriptive epidemiological analysis was carried out from temporal, regional, demographic and vaccine-specific distributions, and AEFI reporting rate was calculated. From 2009 to 2024, a total of 3,420 cases of AEFI associated with NIP vaccines were reported, with an annual average reporting rate of 15.8 per 100,000 doses. Among these, the reporting rate of common vaccine reactions was 14.87 per 100,000, and that of rare vaccine reactions was 0.54 per 100,000. Differences in reporting rates between districts were statistically significant (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.